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The aim of the study was to investigate changes of the olfactory and gustatory capacity in
patients with multiple sclerosis (MS).
Methodology
20 MS patients were tested longitudinally for 3 years after initial testing. The Threshold Dis-
crimination Identification test (TDI) was used for subjective olfactometry. Objective olfacto-
metry was performed by registering olfactory evoked potentials (OEP) by EEG. The Taste
Strip Test (TST) was used for gustatory testing.
Results
45% of the patients showed olfactory dysfunction in the follow-up TDI test and 50% showed
delayed OEP´s. 20% of the patients showed gustatory dysfunction on follow-up visit. The
patients showed mild disease activity with 0,3 ± 0,5 relapses over the testing period and no
significant change of their olfactory and gustatory capacity. The olfactory capacity for the
discrimination of odors correlated inversely with the number of relapses (r = -0.5, p 0.05).
The patients were aware of their olfactory deficit.
Conclusions
Olfactory and gustatory dysfunction is a symptom in MS patients and may be a useful
parameter to estimate disease progression in MS patients. As the discrimination of odors is
processed in higher central regions of the central nervous system (CNS), the results sug-
gest that olfactory dysfunction could be due to CNS damage.
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Introduction
Multiple Sclerosis (MS) is a chronic inflammatory disease affecting the CNS and typically
follows a relapsing-remitting disease course (RRMS). Approximately 15% of all MS patients
initially present with a primary progressive disease course (PPMS) characterized by con-
stantly increasing physical disability without recovery. The neurological symptoms vary
depending on the region of the brain that is affected by MS lesions [1,2]. Olfactory dysfunc-
tion mainly occurs with Alzheimer´s and Parkinson´s disease and less frequently with other
neurodegenerative diseases [3,4]. Furthermore olfactory dysfunction often presents as a first
symptom of Parkinson´s disease, occurring around 4–6 years before motor disorders begin
[5,6]. Detecting olfactory disorders is becoming increasingly important in the research of
neurological diseases [4]. A dysfunction in the olfactory sense may have a great impact on
quality of life [3].
Recent studies have reported olfactory dysfunction in MS patients ranging from 11 to 41%
[7–10] and gustatory dysfunction ranging from 4.5 to 19% [11–13]. In our longitudinal study
we examined the olfactory and gustatory function in MS patients over a median time interval
of 3 years. The aim of this study was to investigate the correlation between the olfactory and
gustatory capacity and disease progression in the course of disease. To verify the olfactory test
results, olfactory evoked potentials were registered for objective olfactometry.
Materials and Methods
Subjects
20 patients (15 women, 5 men) with diagnosed MS according to the McDonald criteria 2010
[1] were tested longitudinally over a period of 3 years. 16 patients had relapsing remitting MS,
4 patients had primary progressive MS. 14 out of 16 patients with RRMS were treated with dis-
ease-modifying drugs for MS during the testing period. 3 patients received glatiramer acetate,
3 patients interferon beta, 4 patients dimethyl fumarate, 3 patients fingolimod and 1 patient
azathioprine. 2 patients with RRMS and 4 patients with primary progressive MS did not
receive any immunomodulatory or immunosuppressive therapy during the testing period.
On baseline and on follow-up visit, all patients had to complete two questionnaires and
underwent an otorhinolaryngological (ORL) and neurological examination. Predefined exclu-
sion criteria were: age below 18 or over 65, pregnancy, olfactory disorders with a known differ-
ent etiology (post-traumatic, post-infectious, sinonasal, infections of the upper respiratory
tract, allergies, tumours treated with chemotherapy or radiation, patients suffering from
depression, Parkinson´s or Alzheimer´s disease). Additionally, patients taking medications
that could cause olfactory dysfunction, for example penicillamine, certain antibiotics, amitrip-
tyline or methotrexate were excluded. Patients who had received corticosteroid treatment
within the last 3 months before olfactory testing were excluded from the study since corticoste-
roids can affect the olfactory function [14]. The ORL examination was performed prior to the
olfactory testing to exclude olfactory dysfunction caused by any other reasons than MS. A total
score of at least 25 points in the Mini Mental State Examination (MMSE) had to be achieved in
order to identify patients with cognitive dysfunction which was also an exclusion criterion.
The Becks Depression Inventory Test (BDI) was performed to exclude patients with depres-
sion. The BDI is a self-evaluation method to detect the severity of symptoms of depression
[15]. Adapted to the patients in our study we defined a score of below 15 points as an inclusion
criterion. We used the Expanded Disability Status Scale (EDSS) to measure the grade of physi-
cal disability [16]. Patients with a value above 7 were excluded from the study, as they were not
capable of performing all testing procedures.
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Ethical approval and trial registration was obtained by the medical ethics committee of
Charite´, University Hospitals Berlin. Written consent was required to participate in the study.
Olfactory testing
The Threshold Discrimination Identification Test (TDI) was used for orthonasal olfactory test-
ing [17]. The olfactory threshold (T) was measured using 48 Sniffin’ Sticks with a 16-stage dilu-
tion series of n-butanol. The discrimination test (D) was performed with 48 Sniffin’ Sticks of
different smell qualities to test the distinction of smells. Everyday odors such as “fish” or “cof-
fee” were identified with the Identification Test (I), which consisted of 16 Sniffin’ Sticks. A
TDI value of less than 16 points was rated as anosmia, up to 30.5 points as hyposmia and a
value above 30.5 points as normosmia. The patients also estimated their smell function on a
visual analogue scale (VAS) ranging from 0 to 10 points.
Gustatory testing
For gustatory testing, the “Taste Strip Test” (TST) by Burghart Wedel (Germany) was used
[18]. The 16-part test evaluates 4 different qualities of taste (sweet, sour, salty and bitter), each
presented in 4 different concentrations (multiple forced-choice). A test value of below 9 repre-
sents a reduced sense of taste.
Olfactory Evoked Potentials (OEP)
The OM 2/S Olfactometer (Burghart Elektro- und Feinmechanik GmbH, Germany) was used
according to the guidelines of the Working Group of Olfactology and Gustology of the Ger-
man ENT society [19]. A 4 mm lumen tube was placed in the nasal vestibulum and delivered
an airstream which was humidified and warmed to 36.5˚C with a flow of 7–8 l/min. The sti-
muli had a duration of 200ms and were presented in intervals between 35–40 seconds, alter-
nating between the right and left nostril. OEPs were recorded using the international 10–20
EEG system. The olfactory stimuli consisted of phenylethyl alcohol (PEA) and hydrogen sul-
fide (H2S). For the trigeminal stimuli carbon dioxide (CO2) was used. The test results were
interpreted according to the guidelines of the Working Group of Olfactology and Gustology of
the German ENT society [19].
Statistical analysis
Statistical analyses were performed using SPSS 23.0 (IBM SPSS Statistics, New York, USA).
Graphs were created with GraphPadPrism 6.0 (GraphPad Software Inc, California, USA). The
data are presented as means with standard deviations. The Wilcoxon-Man-Whitney-Test was
used to compare baseline with follow-up measurements of clinical characteristics and olfactory
test scores. Spearman correlations were performed to run correlational analyses on the VAS
with TDI score and the number of relapses with the D-score.
Results
Subjects
A total of 8 patients did not perform the follow-up testing. 3 patients had to be excluded due to
corticosteroid treatment they had received and 5 patients refused to perform the follow-up
visit due to personal reasons. The mean EDSS-Score remained with 2 ± 2 points (p = 0.17)
over the testing period. The mean number of relapses during the longitudinal study was
0,3 ± 0,5. The patients clinical characteristics are presented in Table 1.
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Olfactory testing
50% (n = 10) of the longitudinal cohort (n = 20) showed hyposmia in the baseline TDI test. In
the follow-up testing 45% of the patients (n = 9) showed hyposmia. None of the patients were
anosmic. Interestingly, the overall TDI score remained stable (30.6 vs 30.8 points, p = 0,78)
over the testing period with a mean disease duration of 3.2 years. Furthermore all olfactory
subscores (Threshold, Discrimination, Identification) showed no significant change during
the longitudinal study. The results of the baseline and follow-up TDI measurements are pre-
sented in Table 2 and Fig 1. Olfactory raw data is presented in a supplementary table (S1
Table).
Gustatory testing
20% of the patients displayed a gustatory dysfunction in the baseline measurement and in the
follow-up visit. 75% of the patients with a gustatory dysfunction were also hyposmic. Gustatory
test results are presented in Table 2.
Olfactory evoked potentials
In the follow-up test, objective olfactometry was also performed. 50% of the patients showed
delayed OEP´s and were classified as hyposmic. These patients had a mean TDI score of 29.
The patients that were classified as normosmic in objective olfactometry had a mean TDI
score of 33 points.
Table 2. Olfactory and Gustatory data.
Mean ± Standard Deviation Minima / Maxima
TDI 30.8 (30.6) ± 5.7 (5) 19 (23) / 38 (39)
T 8 (6.6) ± 2,9 (1.9) 3 (3) / 13 (10)
D 12 (12) ± 2.4 (3) 6 (6) / 16 (15)
I 11 (12) ± 2.5 (2) 4 (8) / 13 (16)
VAS 7.7 (7) ± 1.8 (1.5) 3 (4) / 10 (9)
TST 10 (9.5) ± 3.1 (6) 6 (3) / 15 (16)
Follow up values (bold) and baseline values (brackets) [TDI = Threshold Discrimination Identification,
T = Threshold, D = Discrimination, I = Identification, VAS = Visual Analogue Scale, TST = Taste Strip Test].
The data are presented as means with standard deviations. Sample maxima and minima are indicated.
doi:10.1371/journal.pone.0170492.t002
Table 1. Demographics and clinical characteristics.
Mean ± Standard Deviation Minima / Maxima
Age 44.9 (41.8) ± 10.1 (10.1) 26.7(23.3) / 64 .8 (62.8)
DD 9 (6.2) ± 7.8 (7.8) 2 (0) / 33 (31)
EDSS 2 (2) ± 2 (2) 1 (1) / 6 (6)
TR 3.6 (3.3) ± 3.7 (3.6) 1 (1) / 16 (15)
BDI 7 (6) ± 5.2 (5) 0 (0) / 15 (14)
MMSE 29 (29) ± 1.8 (1) 25 (27) / 30 (30)
Follow up values (bold) and baseline values (brackets) [DD = Disease Duration, TR = total number of
relapses, EDSS = Expanded Disability Status Scale, BDI = Becks Depression Inventory, age and DD are
presented in years]. The data are presented as means with standard deviations. Sample maxima and
minima are indicated.
doi:10.1371/journal.pone.0170492.t001
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However the total number of relapses correlated with a reduced Discrimination-Score
(r = -0.5, p 0.05). The VAS scale correlated with the TDI score of the longitudinally tested
patients (r = 0.6 p 0.01) [Fig 2].
The patients showed mild disease activity with a mean number of 0,3 ± 0,5 relapses over the
testing period and no significant change of their olfactory and gustatory capacity. Furthermore
the patients showed a good self-estimation of their olfactory capacity expressed on the VAS.
Discussion
We reported olfactory dysfunction in 45% of the longitudinally tested MS patients. Our results
conform with previous studies, which reported olfactory dysfunction at rates of 11%–41% [7–
10]. The olfactory capacity might have varied as different smell tests, such as the TDI test, the
Fig 1. Boxplot of longitudinal TDI testing results. X-axis: time points (baseline and follow-up in years). Y-
axis: TDI score (TDI = Threshold Discrimination Identification). The median is shown with first and third
quartiles. The scores of the whiskers represent the minimum and maximum scores.
doi:10.1371/journal.pone.0170492.g001
Fig 2. Linear correlation of TDI score with VAS. X-axis: VAS score (VAS = Visual Analogue Scale). Y-axis:
TDI score (TDI = Threshold Discrimination Identification). p 0.01, r = 0.6 (Pearson correlation coefficient).
doi:10.1371/journal.pone.0170492.g002
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University of Pennsylvania Smell Identification Test (UPSIT) and Brief Smell Identification
Test (B-SIT) were applied in the previous studies. Most of these studies grouped MS patients
with relapsing remitting disease course and chronic progressive disease course together [7–
13]. Interestingly, the olfactory and gustatory capacity of the MS patients remained stable dur-
ing the longitudinal testing period in our study. The grade of physical disability expressed in
the EDSS score also didn´t increase. These findings might be due to disease-modifying therapy
that 70% of the patients were receiving. 75% of the patients with a gustatory dysfunction were
also hyposmic. On a cortical level, the olfactory and the gustatory system intersect, in the insu-
lar cortex, the orbitofrontal cortex and the amygdala [20]. Olfactory stimuli are linked with
gustatory information, delivered to the anterior insula (multimodal integration), which might
explain these results.
The functional deficit in MS is caused by a demyelinating process leading to reduced con-
duction and inhibition in the transmission of electrophysiological impulses and secondary to
an axonal degeneration [2]. A human autopsy cohort reported olfactory bulb/tract and inferior
frontal cortex demyelination in 70.6% of pathologically confirmed MS cases [21]. The results
from this study further support the findings of olfactory dysfunction in MS patients. Olfactory
dysfunction in MS patients have been illustrated by a delayed latency and reduced amplitude
of OEP´s in different studies [22, 23]. Patients showing pathological OEP´s in our study also
showed olfactory dysfunction in subjective olfactory testing, which suggests a good reliability
of our testing procedures. Visual, sensory, motor-evoked and acoustic-evoked potentials are
clinically routine procedures used for diagnosing MS. OEP´s might serve as an additional tool
in certain cases to detect a functional deficit in the olfactory pathway. Most of the MS patients
showed a good self-perception of their olfactory capacity. Their self-estimation of smell was
slightly higher (not significant) in the follow-up visit, which could be due to an adaptive pro-
cess of the olfactory deficit. This shows that testing the olfactory capacity might be a useful
additional parameter to estimate disease activity for MS patients concerning the dynamic
course of their disease.
The Discrimination-Score (D-Score) was correlated with the total number of relapses dur-
ing the testing period. As the discrimination of odors is processed in higher central regions of
the CNS [21], this result suggests that olfactory dysfunction might occur due to CNS damage
in MS patients, rather than from peripheral damage of the olfactory nerve. A different study
group showed a close association longitudinally between magnetic resonance imaging (MRI)
activity measured as remission and exacerbation of plaque numbers and the olfactory function
in 5 patients over an 18–20 month period [24]. A correlation between the olfactory bulb vol-
ume and the olfactory capacity of patients with olfactory dysfunction with different etiologies
has been demonstrated in several studies [25, 26, 27]. Our previous study showed a correlation
between a decreased olfactory bulb and olfactory brain volume and increased numbers and
volumes of MS lesions in the olfactory brain of MS patients [9]. These results further suggest a
correlation between the olfactory function and disease activity in MS patients. Olfactory dys-
function in MS patients might be due to MS lesions or atrophy in the olfactory brain. Our
study could be improved by the use of MRI to measure the lesion load and volume changes of
the olfactory bulb and the olfactory brain. The application of contrast agent would have been
useful to detect enhanced MS lesions and measure subclinical disease activity.
The results from this study underline the persistence of olfactory and gustatory dysfunction
in MS patients. This suggests that the olfactory capacity for the discrimination of smells might
be a marker for disease progression in MS patients. We reported a case of one MS patient pre-
senting functional anosmia and gustatory dysfunction during an acute relapse; showing a sig-
nificant improvement of his chemosensory function in a follow-up test one year later [28]. The
incidence of olfactory dysfunction with acute relapses and improvement of olfactory function
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during the course of the disease suggests that acute olfactory disturbance might occur due to
damage to the olfactory bulb. Given its plasticity, the olfactory bulb is able to recover from
acute damage [29].
This study is possibly the first investigation into olfactory and gustatory function in more
than 5 MS patients longitudinally. The patients in our study showed mild disease activity and
no relevant changes in their olfactory and gustatory function. It would be interesting to per-
form olfactory and gustatory testing in patients with highly active MS to investigate possible
increased olfactory and gustatory disturbances and the correlation to MRI activity.
Supporting Information
S1 Table. Olfactory Raw Data. S1 Table: Follow up values (bold) and baseline values (brack-
ets) [TDI = Threshold Discrimination Identification, T = Threshold, D = Discrimination,
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